Validation of verbal autopsies in rural South Africa: the influence of AIDS m...Annette Gerritsen
Understanding the mortality pattern experienced in South Africa is hampered due to poor quality and representativeness of routinely collected data, particularly in rural areas. Therefore, a mortality surveillance system using verbal autopsy (VA) procedures is used in the Agincourt Health and Demographic Surveillance System (HDSS) as a solution to this problem.
This presentation discusses a re-validation of the Agincourt VA instrument for HIV/AIDS diagnoses and evaluate the effects on other communicable and non-communicable diseases in this era of health transition.
Powepoint On Epidemiological INDICES OF TB
Suitable For Community Medicine Students - KUHS
KERALA MEDICAL BOARD
Prepared By A Student from
Mount Zion Medical College , Chayalode Adoor
Validation of verbal autopsies in rural South Africa: the influence of AIDS m...Annette Gerritsen
Understanding the mortality pattern experienced in South Africa is hampered due to poor quality and representativeness of routinely collected data, particularly in rural areas. Therefore, a mortality surveillance system using verbal autopsy (VA) procedures is used in the Agincourt Health and Demographic Surveillance System (HDSS) as a solution to this problem.
This presentation discusses a re-validation of the Agincourt VA instrument for HIV/AIDS diagnoses and evaluate the effects on other communicable and non-communicable diseases in this era of health transition.
Powepoint On Epidemiological INDICES OF TB
Suitable For Community Medicine Students - KUHS
KERALA MEDICAL BOARD
Prepared By A Student from
Mount Zion Medical College , Chayalode Adoor
Poster presentation at the AIDS 2018 conference in Amsterdam.
By: Marieke J. van der Werf and Csaba Ködmön, European Centre for Disease Prevention and Control, ECDC.
An overview on how European countries have been responding to the HIV epidemic since 2004 based on the commitments as outlined in the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia.
After several years of decreasing trend, foodborne hepatitis A virus (HAV) infection has re-emerged as a public health problem in EU/EEA since 2011. Several consecutive multi-country foodborne HAV outbreaks were experienced in Europe 2012-2014.
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2014, almost 30 000 people were diagnosed in European Union and European Economic Area Member States. This slide set includes maps, graphs and tables from the 2014 HIV/AIDS surveillance report, published jointly by ECDC and WHO Europe.
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2015, almost 30 000 people were diagnosed in European Union and European Economic Area Member States; a rate of 6.3 cases in every 100 000 people (when adjusted for reporting delay).
This report, prepared jointly with the WHO Regional Office for Europe, presents data on HIV and AIDS for the whole European Region, including the EU and EEA countries. Analyses are provided for the EU and EEA region.
Presentation by Camelia Savulescu during the ESCAIDE 2016 parallel session on Vaccine-preventable diseases (2) on 29 November 2016 in Stockholm, Sweden
Epidemiology of Tuberculosis (TB) in Albania 1998-2009iosrphr_editor
Abstract : In Albania, many people erroneously think that tuberculosis (TB) is a disease of the past-an illness
that no longer constitutes a public health threat. Surveillance is an integral part of tuberculosis (TB) control.
Albania has a highTB notification rate and there are doubts about underreporting. The evolution of the
incidence of tuberculosis is presented, together with more detailed figures over the period 1998-2009. These
figures were obtained by the monthly forms (called 14/Sh) compared with the individual notification data.
Objective: To examine the distribution and sources of increased tuberculosis (TB) morbidity and reporting
system deficiencies in the Albania from 1998 through 2009. Metodology: The study is descriptive one conductet
during the period 1998-2009. The statistical analysis is based on data reported from regional level (regional
epidemiological departments) to the central level (Public Health Institute). Results: The main findings were:
discordance between the collected data (individual form) and reported data (monthly form); tuberculosis
incidence rate shows little oscillations which ranges from 6.67 to 9.2 cases/100.000 population; 50% of the
regions show a lack of information on the confirmation of diagnosis and laboratory examination type used for
confirmation. Conclusion: TB disease in high-risk populations where it is difficult to detect, diagnose, and treat;
limitations of current control measures and the need for new tests and treatments, including an effective
vaccine; improving information system, regulation of individual form and personnel training.
Poster presentation at the AIDS 2018 conference in Amsterdam.
By: Marieke J. van der Werf and Csaba Ködmön, European Centre for Disease Prevention and Control, ECDC.
An overview on how European countries have been responding to the HIV epidemic since 2004 based on the commitments as outlined in the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia.
After several years of decreasing trend, foodborne hepatitis A virus (HAV) infection has re-emerged as a public health problem in EU/EEA since 2011. Several consecutive multi-country foodborne HAV outbreaks were experienced in Europe 2012-2014.
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2014, almost 30 000 people were diagnosed in European Union and European Economic Area Member States. This slide set includes maps, graphs and tables from the 2014 HIV/AIDS surveillance report, published jointly by ECDC and WHO Europe.
Although HIV is preventable through effective public health measures, significant HIV transmission continues in Europe. In 2015, almost 30 000 people were diagnosed in European Union and European Economic Area Member States; a rate of 6.3 cases in every 100 000 people (when adjusted for reporting delay).
This report, prepared jointly with the WHO Regional Office for Europe, presents data on HIV and AIDS for the whole European Region, including the EU and EEA countries. Analyses are provided for the EU and EEA region.
Presentation by Camelia Savulescu during the ESCAIDE 2016 parallel session on Vaccine-preventable diseases (2) on 29 November 2016 in Stockholm, Sweden
Epidemiology of Tuberculosis (TB) in Albania 1998-2009iosrphr_editor
Abstract : In Albania, many people erroneously think that tuberculosis (TB) is a disease of the past-an illness
that no longer constitutes a public health threat. Surveillance is an integral part of tuberculosis (TB) control.
Albania has a highTB notification rate and there are doubts about underreporting. The evolution of the
incidence of tuberculosis is presented, together with more detailed figures over the period 1998-2009. These
figures were obtained by the monthly forms (called 14/Sh) compared with the individual notification data.
Objective: To examine the distribution and sources of increased tuberculosis (TB) morbidity and reporting
system deficiencies in the Albania from 1998 through 2009. Metodology: The study is descriptive one conductet
during the period 1998-2009. The statistical analysis is based on data reported from regional level (regional
epidemiological departments) to the central level (Public Health Institute). Results: The main findings were:
discordance between the collected data (individual form) and reported data (monthly form); tuberculosis
incidence rate shows little oscillations which ranges from 6.67 to 9.2 cases/100.000 population; 50% of the
regions show a lack of information on the confirmation of diagnosis and laboratory examination type used for
confirmation. Conclusion: TB disease in high-risk populations where it is difficult to detect, diagnose, and treat;
limitations of current control measures and the need for new tests and treatments, including an effective
vaccine; improving information system, regulation of individual form and personnel training.
Summary slides on the epidemiological situation in the EU/EEA.
2018 surveillance data.
Report and ppt slides available from: http://bit.ly/HIVAIDSsurv18
Presentation during the 17th European AIDS Conference (EACS) 2019 looking at the status of HIV pre-exposure prophylaxis PrEP in Europe..
Presenter: Teymur Noori, European Centre for Disease Prevention and Control (ECDC)
Presentation from the opening session of the 17th European AIDS Conference (EACS) 2019, Basel, Switzerland.
Presenter: Anastasia Pharris, European Centre for Disease Prevention and Control.
ECDC symposium "Responding to two of the main STI threats of our time: syphilis and antimicrobial resistant Neisseria gonorrhoeae"
Presentation by: Otilia Mårdh
Presented at: IUSTI 2019, Tallinn
Hepatitis E is one of the most common causes of acute hepatitis in the EU/EEA but currently not notifiable at EU level.
This presentation summarises ECDC's work on the topic and survey results on hepatitis E on 2005 to 2015 data.
Any questions? Contact press@ecdc.europa.eu
This presentation summarises the main data from the ECDC Annual epidemiological reports 2017 on chlamydia, gonorrhoea, lymphogranuloma venereum, (congenital) syphilis
Providing an overview on data, trends and summary of findings on the hepatitis B and C surveillance data from EU/EEA countries for the year 2017:
Find ECDC's Annual Epidemiological reports online: http://bit.ly/ECDCAER
HIV transmission remains a major public health concern and affects more than 2 million people in the WHO European Region.
These ECDC slides summarise findings from the report which is available via http://bit.ly/WAD_18
Presentation at European Harm Reduction Conference
Bucharest, 21 November 2018
Author Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC)
What is the current situation of HIV in Europe and Central Asia?
How can we more effectively prevent new infections?
Presentation by Anastasia Pharris,
European Centre for Disease Prevention and Control (ECDC)
at Glasgow HIV Drug Therapy Conference
28 October 2018
Data and trends from the ECDC Annual Epidemiological reports for 2016 on:
Chlamydia (http://bit.ly/AERch16)
Lymphogranuloma venereum (http://bit.ly/AERLGV16)
Gonorrhoea (http://bit.ly/AERsy16)
Syphilis (http://bit.ly/AERsy16)
Congenital syphilis (http://bit.ly/AERcs16)
See also: https://ecdc.europa.eu/en/annual-epidemiological-reports
Teymur Noori, ECDC
22nd International AIDS Conference, Amsterdam 2018
2018 European African HIV/AIDS & Hepatitis C Community Summit. "Our Voices Matter for a lasting solution!!"
More from European Centre for Disease Prevention and Control (20)
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
NVBDCP.pptx Nation vector borne disease control program
Comparison of virus detections reported as sentinel or non-sentinel by EU/EEA countries
1. Comparison of virus detections
reported as sentinel or non-sentinel
by EU/EAA countries
Joint WHO/Europe & ECDC Annual Influenza Surveillance Meeting
Vienna, 11-13 June 2014
2. Number of tested specimens
Discrepancies between number of tested samples in sentinel/non-sentinel across countries:
Different populations sampled in non-sentinel across countries?
Comparability?
3. Non-sentinel data sources
Countries General
practices
Paediatric
practices
Polyc
linics
ICU/
critical
care
General/
internal
medicine
Paediatric
hospitals
Maternity
wards
Infectious
disease
hospital
wards
Respiratory
disease
hospital
wards
Chronic
disease
hospital
wards
Specimens
collected during
respiratory
disease outbreaks
Other
AT
BE
BG
DK
EE
GR
HU
IS
IT
LV
LT
MT
NO
PL
PT
SK
SE
IE
4. Percentage of flu-positive specimens by
surveillance system and week, 2010/11-
2013/14
Max. sentinel
Max. non-sentinel
Season threshold
Discrepancies in sentinel/non-sentinel overall data for season estimate:
How can non-sentinel data be used?
6. Summary
Number of specimens tested vary between seasons and
differ between countries -> different source populations
of non-sentinel specimens?
Positivity rate in non-sentinel differs to sentinel over
weeks, lower amplitude and smaller number of week
above 10% threshold – added value for season
estimates?
Distribution of types and subtypes differ between
sentinel and non-sentinel specimens – how to interpret?
7. Points to be discussed
Non-sentinel data are collected differently in every country
(general practice and primary care, hospitals, ICU, outbreaks etc):
1. How should we pool the data at the Regional level?
2. What is the added value of the non-sentinel data and how can non-
sentinel data be useful?
3. Which non-sentinel data should be reported from every country?
4. How should non-sentinel data be displayed, compared and
reported in the joint bulletin?